Comparison of thrice weekly vs daily human leucocyte interferon-α therapy for chronic hepatitis C

Journal of Viral Hepatitis

Volumn 6, Issue 4, 1999, Pages 321-327

  Chemello, L ^a   Cavalletto, L ^a   Bernardinello, E ^a   Boccato, S ^a   Casarin, P ^b   Cavinato, F ^c   Urban, F ^d   Pontisso, P ^a   Cecchetto, A ^a   Gatta, A ^a   Alberti, A ^a   Donadon, Valter ^e   Donada, Carlo ^e   Frezza, Mario ^d   Belussi, Fabio ^c  

^a UNIVERSITY OF PADOVA   (Italy)

^b Sacile Hospital   (Italy)

^c Le Grazie Venezia Hospital   (Italy)

^d UNIVERSITY OF TRIESTE   (Italy)

^e Pordenone Hospital   (Italy)

Author keywords

Chronic hepatitis C; Daily dose; Human leucocyte IFN ; IFN therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS C ANTIBODY; IMMUNOGLOBULIN; PROTEIN; VIRUS RNA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; IMMUNOBLOTTING; INTRAMUSCULAR DRUG ADMINISTRATION; IRRITABILITY; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MYALGIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LEUKOCYTES; LIVER; MALE; MIDDLE AGED; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0032875997     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1999.00165.x     Document Type: Article

References (18)

1. Sceff LB, Buskell-Bales Z, Wright EC et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992; 327: 1906-1911.
2. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic post-transfusion hepatitis. Hepatology 1991; 14: 969-974.
3. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-1466.
4. Lee WM. Therapy of hepatitis C. Interferon alfa-2a trials. Hepatology 1997; 26: 89S-95S.
5. Carithers RL Jr, Scott SE. Therapy of hepatitis C. Metaanalysis of interferon alfa-2b trials. Hepatology 1997; 26: 83S-88S.
6. Poynard P, Leroy V, Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-789.
7. Reichard O, Norkrans G, Frydén A, Braconier JH, Sonnerborg A, Weiland O, for the Swedish Study Group. A randomized, double-blind, placebo-controlled trial of interferon α-2a with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-87.
8. Chemello L, Bonetti P, Cavalletto L et al., and the TVVH Group. Randomized trial comparing three different regimens of alpha-interferon in chronic hepatitis C. Hepatology 1995; 22: 700-706.
9. The Australian Hepatitis C Study Group. Efficacy and tolerance of a 6-month treatment course of daily interferon-α2a for chronic hepatitis C with cirrhosis. J Viral Hep 1997; 4: 317-323.
10. Enomoto E, Kurosaki M, Tanaka Y, Marumo F, Sato C. Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism. J Gen Virol 1994; 75: 1361-1369.
11. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26: 226-231.
12. Zeuzem S, Schmidt JM, Lee JH, Brigitte R, Roth WK. Effect of interferon-alpha on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996; 23: 366-371.
13. Farrell GC, Bacon BR, Goldin RD. The Clinical Advisory Group for the Hepatitis C Comparative Study. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an International randomized controlled trial. Hepatology 1998; 27: 1121-1127.
14. Morisco F, Concetta T, Iasevoli P, Sessa G, Brunasso G, Caporaso N. Chronic hepatitis C long-term responders to human leukocyte interferon-alpha therapy: persistence of a sustained biochemical and virological response during 5 years of surveillance. Eur J Gastroenterol Hepatol 1998; 10: 399-103.
15. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
16. Pontisso P, Ruvoletto MG, Nicoletti M et al. Distribution of three major HCV genotypes in Italy. A multicentric study of 495 patients with chronic hepatitis C. J Viral Hep 1995; 2: 33-38.
17. Dixon WJ, Ed. BMDP Statistical Software Manual. California University Press, Berkeley, CA, USA, 1992.
18. Dusheiko G. Side effects of alpha-interferon in chronic hepatitis C. NIH consensus development conference on management of hepatitis C. Hepatol 1997; 26 (suppl 1): 112S-121S.